Résumé
ObjectiveTo investigate the effect of Buchangwenxin particles in maximum P wave (Pmax), dispersion of P wave(Pd) of elder patients with diastolic cardiac dysfunction and paroxysmal atrial fibrillation(PAF).Methods115 elder patients with diastolic cardiac dysfunction and PAF were randomly divided into two groups:group A received the routine drug therapy,and group B received Buchangwenbxin particles with routine drug therapy.Another 54 elder patients with diastolic cardiac function but without PAF was selected as control group.Changes in Pmax and Pd were compared between groups with or without PAF as well as subgroups.ResultsPmax and Pd were wider in PAF group than no PAF group(all P ＜0.01).There was no difference between group A and B in Pmax and Pd (all P＞ 0.05), and there were less atrial fibrillation as well as shortened Pmax and Pd in group B, which was significantly different with group A(all P ＜0.01).ConclusionPmax and Pd were wider in elder patients with diastolic cardiac dysfunction and PAF than those without PAF,and Buchangwenxin particles could shorten Pmax and Pd and reduce the attacks of atrial fibrillation.
Résumé
Objective To study the efficacy of trimetazidine combined with perindopril in treating congestive heart failure (CHF). Methods One hundred and eighteen patients with CHF were randomly divided into experimental group and control group. All patients were given conventional medical treatment. Patients in the control group was treated with additionally with perindopril. The initial dose was 2 mg/d, and gradually increased to target dose of 4 mg/d. The experimental group was additionally treated with trimetazidine 20 mg orally 3 times a day for 12 weeks based on the regimen in the control group. The changes of left ventricular ejection fraction ( LVEF) , left ventricular end of diastolic volume ( LVEDV) , left ventricular end of systolic volume ( LVESV), stroke volume (SV),cardiac output (CO)and cardiac function (NYHA) were observed. Results In the experiment group, after treatment,LVEF,LVEDV,LVESV,CO and SV were(46. 89 ±8. 00)% ,(129. 20 ±25. 00)ml, (70.90 ±32. 00)ml, (4. 32 ±0. 65 ) L/min and (55. 06 ± 13. 27) ml, respectively, which were significantly improved compared to those before treatment (29.60 ± 11. 00)% ,(164. 40 ± 31. 00) ml, (95. 60 ± 33. 00) ml, (2.91 ±0.56) L/min and (37. 69 ± 13. 62) ml .respectively) ( P < 0.01 or P < 0. 05). After treatment, the LVEF, LVEDV, LVESV, CO and SV were (46.89 ± 8. 00)% , (34. 70 ± 9. 00)% ,( 129. 20 ± 25. 00) ml, ( 148. 20 ±29. 00) ml and (70.90 ± 32. 00)ml in the experiment group, respectively, which were significantly higher than those in the control group (81. 10 ±31.00)ml, (4. 32 ±0.65) L/min, (3. 14 ±0.60) L/min, (55. 06 ±13.27 )ml and (49. 56 ± 14. 29) ml, respectively) (P <0. 01 or P <0. 05). The overall effective rate in the experiment group was 93. 2% .which was significantly higher than that in the control group (66. 1% ) ( P < 0.01). No obvious adverse effect was observed. Conclusions The effect of trimetazidine combined with perindopril in treating congestive heart failure is satisfactory. It is safe and effective for CHF.